Prelude Therapeutics Incorporated

The call did not include quarterly revenue, EPS, or gross margin figures. On the hard-number side, Incyte paid $35 million upfront and purchased $25 million of Prelude nonvoting common stock at $4 per share, for $60 million total at signing; if exercised, the option includes an additional $100 million upfront payment, up to $775 million more in milestones, and single-digit royalties, for up to $910 million in total cash payments and future milestones. Prelude said the JAK program is planned for IND filing in first quarter 2026 and Phase I initiation in the first half of 2026, while the KAT6A program is on track for IND filing in mid-2026 and Phase I start in the second half of 2026. Management also said the company has runway into 2027.

Kris Vaddi framed the quarter as a strategic reset, saying Prelude made decisions to sharpen R&D focus, optimize capital allocation, and concentrate on programs with the highest probability of success. He emphasized that the company is entering 2026 with two lead assets targeting clinically validated pathways and a clear path to the clinic, while also advancing early DAC work and preparing additional ASH data. His tone was upbeat and confident, but grounded in execution, with repeated focus on differentiation, clinical validation, and disciplined capital use.

Bryant Lim handled the opening and regulatory framing, with the main financial message coming through the business update rather than a standard earnings presentation. The key financial points were the Incyte transaction terms: $35 million upfront, $25 million equity investment at $4 per share, $100 million more if the option is exercised, up to $775 million in milestones, and single-digit royalties, with total potential value of up to $910 million. Management also said the deal and broader capital actions enhanced the company’s financial position and provide runway into 2027.

Analysts focused on how Prelude plans to develop the JAK2V617F and KAT6A programs, especially relative to competitors that are already ahead in the clinic. Management said the JAK program would likely start in myelofibrosis first, with high-risk PV and ET as additional options, while KAT6A would start in ER-positive breast cancer as monotherapy and then move quickly into fulvestrant combinations if the clinic confirms the preclinical differentiation. Questions also addressed companion diagnostics, with management saying routine qPCR-style V617F testing is standard in MPN and would be used as the program advances. On capital and timing, management said JAK would be in dose escalation in 2026 and KAT6 clinical updates likely won’t come until 2027.